Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of this study is to evaluate the safety, tolerability, drug-levels, drug-effects and preliminary anti-tumor activity of DF6002 alone and in combination with Nivolumab in participants with advanced solid tumors.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Other protocol-defined inclusion/exclusion criteria apply
Primary purpose
Allocation
Interventional model
Masking
473 participants in 6 patient groups
Loading...
Central trial contact
Sean Rossi
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal